The non-classical class Ib molecule human leukocyte antigen E (HLA-E) has limited polymorphism and can bind HLA class Ia leader peptides (VL9). HLA-E-VL9 complexes interact with the natural killer (NK) cell receptors NKG2A-C/CD94 and regulate NK cell-mediated cytotoxicity. Here we report the isolation of 3H4, a murine HLA-E-VL9-specific IgM antibody that enhances killing of HLA-E-VL9-expressing cells by an NKG2A+ NK cell line. Structural analysis reveal that 3H4 acts by preventing CD94/NKG2A docking on HLA-E-VL9. Upon in vitro maturation, an affinity-optimized IgG form of 3H4 showes enhanced NK killing of HLA-E-VL9-expressing cells. HLA-E-VL9-specific IgM antibodies similar in function to 3H4 are also isolated from naïve B cells of cytomegalovirus (CMV)-negative, healthy humans. Thus, HLA-E-VL9-targeting mouse and human antibodies isolated from the naïve B cell antibody pool have the capacity to enhance NK cell cytotoxicity.

Department of Cell Biology Charles University Prague 12800 Czech Republic

Department of Immunology Duke University School of Medicine Durham NC 27710 USA

Department of Medicine Duke University School of Medicine Durham NC 27710 USA

Department of Surgery Duke University School of Medicine Durham NC 27710 USA

Division of Structural Biology Wellcome Centre for Human Genetics University of Oxford Oxford OX3 7BN UK

Duke Human Vaccine Institute Duke University School of Medicine Durham NC 27710 USA

Nuffield Department of Clinical Medicine University of Oxford Oxford OX3 7FZ UK

Zobrazit více v PubMed

Raulet DH. Missing self recognition and self tolerance of natural killer (NK) cells. Semin Immunol. 2006;18:145–150. PubMed

Yokoyama WM, Kim S. How do natural killer cells find self to achieve tolerance? Immunity. 2006;24:249–257. PubMed

Chiossone L, Dumas PY, Vienne M, Vivier E. Natural killer cells and other innate lymphoid cells in cancer. Nat. Rev. Immunol. 2018;18:671–688. PubMed

Andre P, et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell. 2018;175:1731–1743 e1713. PubMed PMC

Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK. Cell Recognit. Immunol. Today. 1990;11:237–244. PubMed

Ljunggren HG, Karre K. Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J. Exp. Med. 1985;162:1745–1759. PubMed PMC

Karlhofer FM, Ribaudo RK, Yokoyama WM. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature. 1992;358:66–70. PubMed

Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science. 1995;268:405–408. PubMed

Pende D, et al. Killer Ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front. Immunol. 2019;10:1179. PubMed PMC

Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 1997;27:1164–1169. PubMed

Brooks AG, Posch PE, Scorzelli CJ, Borrego F, Coligan JE. NKG2A complexed with CD94 defines a novel inhibitory natural killer cell receptor. J. Exp. Med. 1997;185:795–800. PubMed PMC

Braud VM, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998;391:795–799. PubMed

Andre P, et al. Differential regulation of killer cell Ig-like receptors and CD94 lectin-like dimers on NK and T lymphocytes from HIV-1-infected individuals. Eur. J. Immunol. 1999;29:1076–1085. PubMed

Mahapatra S, et al. High-resolution phenotyping identifies NK cell subsets that distinguish healthy children from adults. PLoS ONE. 2017;12:e0181134. PubMed PMC

Kraemer T, Blasczyk R, Bade-Doeding C. HLA-E: a novel player for histocompatibility. J. Immunol. Res. 2014;2014:352160. PubMed PMC

Hu W, Wang G, Huang D, Sui M, Xu Y. Cancer immunotherapy based on natural killer cells: current progress and new opportunities. Front. Immunol. 2019;10:1205. PubMed PMC

Kim N, et al. Natural killer cells as a promising therapeutic target for cancer immunotherapy. Arch. Pharm. Res. 2019;42:591–606. PubMed

Souza-Fonseca-Guimaraes F, Cursons J, Huntington ND. The emergence of natural killer cells as a major target in cancer immunotherapy. Trends Immunol. 2019;40:142–158. PubMed

van Hall T, et al. Monalizumab: inhibiting the novel immune checkpoint NKG2A. J. Immunother. Cancer. 2019;7:263. PubMed PMC

van Montfoort N, et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell. 2018;175:1744–1755 e1715. PubMed PMC

Lee N, Goodlett DR, Ishitani A, Marquardt H, Geraghty DE. HLA-E surface expression depends on binding of TAP-dependent peptides derived from certain HLA class I signal sequences. J. Immunol. 1998;160:4951–4960. PubMed

Lee N, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl Acad. Sci. USA. 1998;95:5199–5204. PubMed PMC

Aldrich CJ, et al. Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen. Cell. 1994;79:649–658. PubMed

Llano M, et al. HLA-E-bound peptides influence recognition by inhibitory and triggering CD94/NKG2 receptors: preferential response to an HLA-G-derived nonamer. Eur. J. Immunol. 1998;28:2854–2863. PubMed

Kaiser BK, Pizarro JC, Kerns J, Strong RK. Structural basis for NKG2A/CD94 recognition of HLA-E. Proc. Natl Acad. Sci. USA. 2008;105:6696–6701. PubMed PMC

Rolle A, Meyer M, Calderazzo S, Jager D, Momburg F. Distinct HLA-E peptide complexes modify antibody-driven effector functions of adaptive NK cells. Cell Rep. 2018;24:1967–1976 e1964. PubMed

Michaelsson J, et al. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J. Exp. Med. 2002;196:1403–1414. PubMed PMC

van Meijgaarden KE, et al. Human CD8+ T-cells recognizing peptides from Mycobacterium tuberculosis (Mtb) presented by HLA-E have an unorthodox Th2-like, multifunctional, Mtb inhibitory phenotype and represent a novel human T-cell subset. PLoS Pathog. 2015;11:e1004671. PubMed PMC

Joosten SA, et al. Mycobacterium tuberculosis peptides presented by HLA-E molecules are targets for human CD8 T-cells with cytotoxic as well as regulatory activity. PLoS Pathog. 2010;6:e1000782. PubMed PMC

Hansen SG, et al. Broadly targeted CD8(+) T cell responses restricted by major histocompatibility complex E. Science. 2016;351:714–720. PubMed PMC

Walters LC, et al. Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nat. Commun. 2018;9:3137. PubMed PMC

Kraemer T, et al. HLA-E: presentation of a broader peptide repertoire impacts the cellular immune response-implications on HSCT outcome. Stem Cells Int. 2015;2015:346714. PubMed PMC

Sensi M, et al. Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzyme peroxiredoxin 5. Int. Immunol. 2009;21:257–268. PubMed

Taurog, J. et al. in Transgenic Mice and Mutants in MHC Research. 268–275 (Springer, 1990).

Yu YY, Netuschil N, Lybarger L, Connolly JM, Hansen TH. Cutting edge: single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells. J. Immunol. 2002;168:3145–3149. PubMed

Marin R, et al. Analysis of HLA-E expression in human tumors. Immunogenetics. 2003;54:767–775. PubMed

Lampen MH, et al. Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2. Mol. Immunol. 2013;53:126–131. PubMed

Petrie EJ, et al. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence. J. Exp. Med. 2008;205:725–735. PubMed PMC

Sathe, A. & Cusick, J. K. In Biochemistry, Immunoglobulin M. (StatPearls, 2021).

Giltiay NV, Giordano D, Clark EA. The plasticity of newly formed B cells. J. Immunol. 2019;203:3095–3104. PubMed PMC

Kepler TB, et al. Reconstructing a B-cell clonal lineage. II. mutation, selection, and affinity maturation. Front. Immunol. 2014;5:170. PubMed PMC

DeKosky BJ, et al. In-depth determination and analysis of the human paired heavy- and light-chain antibody repertoire. Nat. Med. 2015;21:86–91. PubMed

DeKosky BJ, et al. Large-scale sequence and structural comparisons of human naive and antigen-experienced antibody repertoires. Proc. Natl Acad. Sci. USA. 2016;113:E2636–E2645. PubMed PMC

Morales-Buenrostro LE, et al. “Natural” human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation. 2008;86:1111–1115. PubMed

Alberu J, et al. A non-allogeneic stimulus triggers the production of de novo HLA antibodies in healthy adults. Transpl. Immunol. 2007;18:166–171. PubMed

Ravindranath MH, Kaneku H, El-Awar N, Morales-Buenrostro LE, Terasaki PI. Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of anti-HLA-E-positive sera. J. Immunol. 2010;185:1935–1948. PubMed

Ravindranath MH, et al. HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies. Mol. Immunol. 2010;47:1121–1131. PubMed

McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ. Transplant. Transplant. 2000;69:319–326. PubMed

Hickey MJ, Valenzuela NM, Reed EF. Alloantibody generation and effector function following sensitization to human leukocyte antigen. Front. Immunol. 2016;7:30. PubMed PMC

Tomasec P, et al. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. Science. 2000;287:1031. PubMed

Sullivan LC, et al. The presence of HLA-E-restricted, CMV-specific CD8+ T cells in the blood of lung transplant recipients correlates with chronic allograft rejection. PLoS ONE. 2015;10:e0135972. PubMed PMC

Guillerey C, Huntington ND, Smyth MJ. Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 2016;17:1025–1036. PubMed

Lowry LE, Zehring WA. Potentiation of natural killer cells for cancer immunotherapy: a review of literature. Front. Immunol. 2017;8:1061. PubMed PMC

Creelan BC, Antonia SJ. The NKG2A immune checkpoint-a new direction in cancer immunotherapy. Nat. Rev. Clin. Oncol. 2019;16:277–278. PubMed

Klingemann H, Boissel L, Toneguzzo F. Natural killer cells for immunotherapy-advantages of the NK-92 cell line over blood NK cells. Front. Immunol. 2016;7:91. PubMed PMC

Sanchez AM, et al. Development of a contemporary globally diverse HIV viral panel by the EQAPOL program. J. Immunol. Methods. 2014;409:117–130. PubMed PMC

Sanchez AM, et al. The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program for IFN-gamma enzyme-linked immunospot (IFN-gamma ELISpot) assay. J. Immunol. Methods. 2014;409:31–43. PubMed PMC

Moody MA, et al. Toll-like receptor 7/8 (TLR7/8) and TLR9 agonists cooperate to enhance HIV-1 envelope antibody responses in rhesus macaques. J. Virol. 2014;88:3329–3339. PubMed PMC

von Boehmer L, et al. Sequencing and cloning of antigen-specific antibodies from mouse memory B cells. Nat. Protoc. 2016;11:1908–1923. PubMed

Tian M, et al. Induction of HIV neutralizing antibody lineages in mice with diverse precursor repertoires. Cell. 2016;166:1471–1484 e1418. PubMed PMC

Walter TS, et al. A procedure for setting up high-throughput nanolitre crystallization experiments. Crystallization workflow for initial screening, automated storage, imaging and optimization. Acta Crystallogr. D. Biol. Crystallogr. 2005;61:651–657. PubMed PMC

O’Callaghan CA, et al. Structural features impose tight peptide binding specificity in the nonclassical MHC molecule HLA-E. Mol. Cell. 1998;1:531–541. PubMed

Winter G, et al. DIALS: implementation and evaluation of a new integration package. Acta Crystallogr. D. Struct. Biol. 2018;74:85–97. PubMed PMC

Karplus PA, Diederichs K. Linking crystallographic model and data quality. Science. 2012;336:1030–1033. PubMed PMC

Vagin A, Teplyakov A. Molecular replacement with MOLREP. Acta Crystallogr. D. Biol. Crystallogr. 2010;66:22–25. PubMed

Winn MD, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D. Biol. Crystallogr. 2011;67:235–242. PubMed PMC

Afonine PV, et al. Towards automated crystallographic structure refinement with phenix.refine. Acta Crystallogr. D. Biol. Crystallogr. 2012;68:352–367. PubMed PMC

Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of Coot. Acta Crystallogr. D. Biol. Crystallogr. 2010;66:486–501. PubMed PMC

Chen VB, et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D. Biol. Crystallogr. 2010;66:12–21. PubMed PMC

Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 2007;372:774–797. PubMed

Krissinel E, Henrick K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D. Biol. Crystallogr. 2004;60:2256–2268. PubMed

Wrammert J, et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature. 2008;453:667–671. PubMed PMC

Liao HX, et al. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. J. Virol. Methods. 2009;158:171–179. PubMed PMC

Liao HX, et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature. 2013;496:469–476. PubMed PMC

Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front. Immunol. 2019;10:1296. PubMed PMC

Liao HX, et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology. 2006;353:268–282. PubMed PMC

Han, Q. et al. HIV DNA-adenovirus multiclade envelope vaccine induces gp41 antibody immunodominance in Rhesus Macaques. J. Virol.91, 10.1128/JVI.00923-17 (2017). PubMed PMC

Liao HX, et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J. Exp. Med. 2011;208:2237–2249. PubMed PMC

Haynes BF, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005;308:1906–1908. PubMed

Yang G, et al. Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies. J. Exp. Med. 2013;210:241–256. PubMed PMC

Moore JP, Sodroski J. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein. J. Virol. 1996;70:1863–1872. PubMed PMC

Chao G, et al. Isolating and engineering human antibodies using yeast surface display. Nat. Protoc. 2006;1:755–768. PubMed

Benatuil L, Perez JM, Belk J, Hsieh CM. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng. Des. Sel. 2010;23:155–159. PubMed

Delivery of Mycobacterium tuberculosis epitopes by Bordetella pertussis adenylate cyclase toxoid expands HLA-E-restricted cytotoxic CD8+ T cells